Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Blood Pressure Drug Recalled Due to Cancer Risk

Irbesartan tablets have been recalled due to the presence of an impurity believed to cause cancer.

Irbesartan / Image: Stada
Irbesartan / Image: Stada

A November 2nd USA Today article discussed the recall of a blood pressure medication that was recalled due to an impurity linked to cancer. Irbesartan tablets produced by ScieGen Pharmaceuticals are the subjects of the voluntary recall. They were sold in 75, 150, and 300 mg doses and labeled as Westminster Pharmaceuticals and Golden State Medical Supply, Inc.

The drug, which is prescribed to treat high blood pressure and kidney disease, was found to contain N-nitrosodiethylamine (NDEA). NDEA occurs naturally in certain foods, drinking water, air pollution, and industrial processes and is listed as a probable human carcinogen, according to The International Agency for Research on Cancer. ScieGen noted that the company has not been made aware of any adverse events related to the recall.

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?